NME Safety Reviews Expected For Three More Drugs, With FDA Pilot Program Expansion
This article was originally published in The Pink Sheet Daily
Executive Summary
Agency's decision means that analysis of Doribax, Isentress and Bystolic will be forthcoming.
You may also be interested in...
FDA Makes Post-Market Safety Evaluation Comprehensive For All NMEs, BLAs
All new molecular entities and BLAs approved since Sept. 27, 2007, will be subject to the comprehensive post-market safety evaluation process that FDA pilot-tested during the past two years
FDA's Post-Market NME Safety Reviews "Useful," But May Not Continue
Evaluations lead to labeling changes but were resource-intensive, according to agency's final report on a pilot program involving five NMEs.
Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.